Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H16N2O3 |
| Molecular Weight | 248.2777 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(C(=O)NC(=O)NC(C)=O)C1=CC=CC=C1
InChI
InChIKey=GBPZSCQLDXUGNO-UHFFFAOYSA-N
InChI=1S/C13H16N2O3/c1-3-11(10-7-5-4-6-8-10)12(17)15-13(18)14-9(2)16/h4-8,11H,3H2,1-2H3,(H2,14,15,16,17,18)
DescriptionSources: http://rad-ar.or.jp/siori/english/kekka.cgi?n=35325
Sources: http://rad-ar.or.jp/siori/english/kekka.cgi?n=35325
Acetylpheneturide (P-3981/Crampol) is used as an anticonvulsant in the treatment of epilepsy. It is usually used to treat convulsive attacks of epilepsy, psychomotor attacks and autonomic attacks. This medicine suppresses epileptic attacks by acting on the central nerves. The most commonly reported adverse reactions include generalized red rash.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: central nerves Sources: http://rad-ar.or.jp/siori/english/kekka.cgi?n=35325 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CRAMPOL Powder Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://rad-ar.or.jp/siori/english/kekka.cgi?n=35325
for adults, start by taking the dose at 0.3 to 0.4 g, and for children, 0.1 to 0.2 g, three times a day after each meal
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2107062
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
DTXSID8048789
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
100000077973
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
1999
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
G083008IJ0
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
236-493-6
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
m995
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | Merck Index | ||
|
13402-08-9
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
SUB12725MIG
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY | |||
|
72
Created by
admin on Mon Mar 31 18:45:09 GMT 2025 , Edited by admin on Mon Mar 31 18:45:09 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD